AstraZeneca Under Soriot: Progress Report
Last week, AstraZeneca's CEO Pascal Soriot was rumored to be preparing for a move to run Teva Pharmaceutical Industries. This week, he's rumored to be staying put. Scrip takes a look at the key moments in his tenure at the UK big pharma, and the progress on targets.
You may also be interested in...
Global Head of Oncology Dave Fredrickson took over the commercial leadership role in October. Now he is overseeing several key growth drivers, including Imfinizi and Lynparza, while building out a new hematology franchise. Fredrickson talked with Scrip about AstraZeneca's oncology strategy at ASCO.
Pascal Soriot is reportedly about to abandon his top role at UK big pharma AstraZeneca to join Israel's generics giant Teva – a switch that could see him receive a $20m signing bonus, if the rumors are to be believed.